Influenza and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic inflammatory joint: A retrospective study

Joint Bone Spine

Volumn 83, Issue 2, 2016, Pages 155-159

  Brocq, Olivier ^a   Acquacalda, Emilie ^b   Berthier, Frédéric ^c   Albert, Christine ^b   Bolla, Gilles ^d   Millasseau, Elodie ^e   Destombe, Claire ^e   Azulay, Johanna ^d   Asquier, Caroline ^d   Florent, Amélie ^b   Le Seaux, Sylvie ^e   Euller Ziegler, Liana ^b  

^a CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c Division de Radiophysique et de Radioprotection   (Monaco)

^d Centre Hospitalier de Cannes   (France)

^e Service de rhumatologie   (France)

Author keywords

Biological therapy; Chronic inflammatory joint disease; Influenza vaccination; Pneumococcal vaccination

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; USTEKINUMAB;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CHRONIC ARTHRITIS; CROSS-SECTIONAL STUDY; FEMALE; GENERAL PRACTITIONER; HUMAN; INFECTION; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PATIENT INFORMATION; PNEUMOCOCCAL INFECTION; QUESTIONNAIRE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SEASONAL INFLUENZA; SPONDYLARTHRITIS; ADVERSE EFFECTS; AGED; ARTHRITIS, RHEUMATOID; COMPLICATION; INFLUENZA, HUMAN; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES; SPONDYLARTHRITIS; SURVEYS AND QUESTIONNAIRES;

EID: 84959537803     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.11.005     Document Type: Article

References (22)

1. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994, 37:481-494.
2. Doran M.F., Crowson C.S., Pond G.R., et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46:2287-2293.
3. Germano V., Cattaruzza M.S., Osborn J., et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF alpha antagonists. J Transl Med 2014, 12:77.
4. Smitten A.L., Choi H.K., Hochberg M.C., et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008, 35:387-393.
5. Listing J., Gerhold K., Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013, 52:53-61.
6. Leombruno J.P., Einarson T.R., Keystone E.C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta- and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009, 68:1136-1145.
7. Thompson A.E., Rieder S.W., Pope J.E. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2011, 63:1479-1485.
8. Goeb V., Ardizzone M., Arnaud L., et al. Recommendations for using TNFalpha antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health. Joint Bone Spine 2013, 80:574-581.
9. Club rhumatisme et inflammation Fiche pratique du CRI : traitements anti-TNFa et suivi de tolérance 2014, http://www.cri-net.com/.
10. Yoo I.K., Choung R.S., Hyun J.J., et al. Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-alpha therapy. Yonsei Med J 2014, 55:442-448.
11. van Dartel S.A., Fransen J., Kievit W., et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013, 72:895-900.
12. Johnston S.S., Turpcu A., Shi N., et al. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis. Semin Arthritis Rheum 2013, 43:39-47.
13. Curtis J.R., Xie F., Chen L., et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011, 70:1401-1406.
14. Carman W.F., Elder A.G., Wallace L.A., et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000, 355:93-97.
15. Mahamat A., Daures J.P., de Wazieres B. Additive preventive effect of influenza and pneumococcal vaccines in the elderly: results of a large cohort study. Hum Vaccin Immunother 2013, 9:128-135.
16. Weaver A., Troum O., Hooper M., et al. Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in RADIUS 1. J Rheumatol 2013, 40:1275-1281.
17. Lanternier F., Henegar C., Mouthon L., et al. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis 2008, 67:1047.
18. Haroon M., Adeeb F., Eltahir A., et al. The uptake of influenza and pneumococcal vaccination among immunocompromised patients attending rheumatology outpatient clinics. Joint Bone Spine 2011, 78:374-377.
19. Pradeep J., Watts R., Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:837-838.
20. Desai S.P., Turchin A., Szent-Gyorgyi L.E., et al. Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality. Rheumatology (Oxford) 2010, 50:366-372.
21. Doe S., Pathare S., Kelly C.A., et al. Uptake of influenza vaccination in patients on immunosuppressant agents for rheumatological diseases: a follow-up audit of the influence of secondary care. Rheumatology (Oxford) 2007, 46:715-716.
22. Dougados M., Soubrier M., Perrodeau E., et al. Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Ann Rheum Dis 2015, 74:1725-1733.